Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes

Description

While metformin remains the first line treatment in most cases, choices for second line treatment now extend beyond sulfonylureas and include the sodium–glucose cotransporter 2 (SGLT2) inhibitors, glucagon‐like peptide 1 (GLP1) receptor agonists, and dipeptidyl peptidase 4 (DPP4) inhibitors.

 

Learning Outcomes

  • Explain key components of the review.
  • List main recommendations.
  • Recognise changes in management as a result of the review.

 

Authors: Renata Libianto, Timothy ME Davis, Elif I Ekinci

Article Type: Narrative review

 

Medical Journal of Australia
N/A
Reading: journal; textbook; book; literature review
1h : 0m
MBA: 1h : 0m
Endocrine System Diseases
Medical Practitioner, Medical Student, Doctor-in-Training, Non-Vocationally Registered, Researcher, Retired, Specialist - Other, Specialist General Practitioner
You have to be logged in to see the content of this module.

Provided by

  • © 2024 AMA (WA)
  • doctorportal Learning
  • ABN: 65 630 316 942
  • 14 Stirling Highway, Nedlands WA 6009, Australia
  • PO Box 133, Nedlands WA 6009
  • E: enquiries@dplearning.com.au

doctorportal Learning respectfully acknowledges Aboriginal and Torres Strait Islander peoples as the first inhabitants of Australia. We respect the traditional owners of lands across Australia in which our members and staff work and live, and pay respect to their elders past, present and emerging.